在GBD框架下按治疗可及性分级疾病严重程度与可避免负担:以焦虑障碍为例
该案例研究以1997年澳大利亚全国精神健康与福祉调查中焦虑障碍受访者为严重程度来源,结合Cochrane系统综述与网络荟萃分析的治疗效应,按医疗可及质量指数(HAQI)模拟全球焦虑障碍负担。
要点
- GBD焦虑障碍严重程度仅源自单一高收入国家调查,中低收入国家负担可能被低估。
- 按HAQI插值严重程度分布可提高GBD负担估计精度并突出可避免负担。
核心结论
- 基于单一高收入国家调查的GBD焦虑障碍负担可能低估中低收入国家负担。
- 尽管存在有效治疗,低使用率意味着大部分负担仍可避免。
- 若所有焦虑障碍患者获得最优治疗,大部分负担可被避免。
研究设计与样本
- 案例研究,以1997年澳大利亚全国精神健康与福祉调查(NSMHWB)中焦虑障碍受访者为严重程度来源。
- 治疗效应来自Cochrane系统综述数据库并经网络荟萃分析合并。
- 通过基于12项简表调查得分的残疾权重荟萃回归建立严重程度分布。
- 模拟无治疗可及与完全可及最优治疗(认知行为疗法与抗抑郁药)情景下的严重程度变化,沿HAQI线性插值并外推各国严重程度。
主要发现
- 数据库检索获得56篇综述,其中8篇符合纳入标准,报告156项随机对照试验、194个治疗效应。
临床怎么用
- 提示临床与公共卫生从业者关注焦虑障碍治疗可及性与转诊路径的公共推广。
- GBD中按地点特异的严重程度分布可提高负担估计精度并向临床医生突出可避免负担。
- 政策制定者可依据可避免负担比例评估扩大最优治疗覆盖的潜在收益。
局限性
- 严重程度分布基于单一高收入国家(澳大利亚)的单一调查。
- 中低收入国家负担可能被GBD低估。
- 研究为模拟分析,治疗效应来自网络荟萃分析合并的随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Global Burden of Disease Study (GBD) estimates burden by cause with major relevance for resource allocators globally. Non-fatal burden estimates are influenced by disorder severity. However, for many disorders, global severity is sourced from a single high-income country survey. We aimed to estimate severity distributions that vary by Healthcare Access Quality Index (HAQI) using anxiety disorders as a case study and present the usefulness of this method in simulating averted and avoidable burden globally. METHODS: In this case study, we estimated treatment use among respondents with anxiety disorder in the 1997 Australian National Survey of Mental Health and Wellbeing (NSMHWB), the source used to estimate severity of anxiety disorders in GBD. Treatment effects were sourced from the Cochrane Database of Systematic Reviews and pooled via network meta-analysis. Severity distribution was established via a meta-regression of their disability weights, derived from 12-item short form survey scores. We simulated the shift in severity across scenarios without access to treatment and with full access to optimal treatment (cognitive behavioural therapy and antidepressants). We interpolated this shift linearly along the HAQI, extrapolated country-specific severity from HAQI scores, and calculated averted and avoidable burden. FINDINGS: The database review sourced 56 reviews, of which eight were eligible for inclusion. These eight reviews reported on 156 randomised controlled trials, with 194 treatment effects. Respondents to the 1997 NSMHWB consisted of 5936 women (55·8%) and 4705 (44·2%) men aged 18 years or older (mean age and ethnicity data not available). The survey-weighted treatment effect size was -0·28 (95% uncertainty interval -0·45 to -0·12). The pooled treatment effect for full coverage optimal treatment was -1·07 (-1·47 to -0·64). The sequela-weighted disability weight among people with anxiety disorder in the NSMHWB was 0·141 (0·042 to 0·275). The estimated disability weight was 0·188 (0·070 to 0·341) after removing the benefits of treatment and 0·056 (0·013 to 0·140) after providing all people with anxiety disorder access to optimal treatment. Globally, 12·5% (4·6 to 21·5) of anxiety disorder burden was averted because of available treatment. However, 71·1% (46·2 to 87·6) of global anxiety disorder burden could be averted if all people with anxiety disorders had access to optimal treatment. INTERPRETATION: Because it is based on guidance from a single survey done in one high-income country, the burden of anxiety disorders in low-income and middle-income countries is probably underestimated by GBD. Despite the availability of effective treatments, low use of these treatments means that most burden is still avoidable. Most of the burden could be averted if all people with anxiety disorders had access to optimal treatment, highlighting the importance of public promotion and referral pathways of treatment for anxiety disorders. Location-specific severity distributions in GBD would greatly increase precision in burden estimates and highlight avertable burden to clinicians, public health practitioners, and policy makers. FUNDING: Queensland Health and Bill & Melinda Gates Foundation.
引用
- Santomauro DF, Purcell C, Whiteford HA, et al. Grading disorder severity and averted burden by access to treatment within the GBD framework: a case study with anxiety disorders. Lancet Psychiatry. 2023. PMID: 36931778. doi:10.1016/S2215-0366(23)00037-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。